Arsenite is a well-known human carcinogen that especially targets skin. The tumor progression locus 2 (Tpl2) gene encodes a serine/threonine protein kinase that is overexpressed in various cancer cells. However, the relevance of Tpl2 in arsenite-induced carcinogenesis and the underlying mechanisms remain to be explored. We show that arsenite increased Tpl2 kinase activity and its phosphorylation in mouse epidermal JB6 P+ cells in a dose-and time-dependent manner. Exposure to arsenite resulted in a marked induction of cyclooxygenase-2 (COX-2) and prostaglandin E 2 (PGE 2 ), important mediators of inflammation and tumor promotion. Treatment with a Tpl2 kinase inhibitor or Tpl2 short hairpin RNA suppressed COX-2 expression and PGE 2 production induced by arsenite treatment, suggesting that Tpl2 is critical in arsenite-induced carcinogenesis. We also found that arsenite-induced phosphorylation of extracellular signalregulated kinases (ERK) or c-Jun NH 2 -terminal kinases (JNK) was markedly suppressed by Tpl2 kinase inhibitor or Tpl2 short hairpin RNA. Inhibition of arsenite-induced ERK or JNK signaling using a pharmacologic inhibitor of ERK or JNK substantially blocked COX-2 expression. Furthermore, inhibition of Tpl2 reduced the arsenite-induced promoter activity of NF-KB and activator protein-1 (AP-1), indicating that NF-KB and AP-1 are downstream transducers of arsenite-triggered Tpl2. Our results show that Tpl2 plays a key role in arseniteinduced COX-2 expression and PGE 2 production and further elucidate the role of Tpl2 in arsenite signals that activate ERK/JNK and NF-KB/AP-1 in JB6 P+ cells. [Cancer Res 2009;69(20):8043-9] 
Introduction
Inorganic arsenic, which exists primarily as arsenite (Fig. 1A) , is a well-known human carcinogen in the natural environment. Arsenic in drinking water is one of the most potent environmental health threats in the United States and worldwide (1) . Chronic intake of arsenic is associated with an increased risk of tumors of the skin, bladder, liver, kidney, lung, and other tissues (2) . In particular, arsenic accumulates in the skin and is linked to hyperkeratosis, pigmentation disorders, and skin cancers, including basal cell carcinoma and squamous cell carcinoma (3) (4) (5) . Although evidence of the carcinogenicity of arsenic in humans is strong, the mechanism by which it produces tumors is not completely understood.
The tumor progression locus 2 (Tpl2) proto-oncogene, also known as Cot or MAP3K8, encodes a serine/threonine protein kinase that is activated by provirus integration in retrovirus-induced T-cell lymphomas and mammary carcinomas (6) (7) (8) . Overexpression of Tpl2 activates the mitogen-activated protein kinase (MAPK) pathway (9, 10) as well as various transcription factors (11) . The activation of Tpl2 is required for the induction of tumor necrosis factor-a by lipopolysaccharide in macrophages (12) . Tpl2 is overexpressed in breast cancer (13) as well as in gastric and colon adenocarcinomas (14) . Therefore, Tpl2 is a critical component of the signaling pathway that controls tumor development.
Cyclooxygenase-2 (COX-2) is an inducible enzyme catalyzing the conversion of arachidonic acid to prostaglandins. COX-2 is induced in many tissues, including the epidermis, in response to inflammation. Upregulation of COX-2 has been found in the early stages of carcinogenesis and appears to be a consistent feature of neoplastic development in a wide variety of human and animal epithelial tissues (15) . Selective COX-2 inhibitors can reduce the incidence of UV-induced squamous cell carcinoma in hairless mice (16) . COX-2-derived bioactive lipids, including prostaglandin E 2 (PGE 2 ), are potent inflammatory mediators that promote tumor growth and metastasis by stimulating cell proliferation, invasion, and angiogenesis (17) . Elevated PGE 2 levels occur in both basal and squamous cell carcinomas of the skin (18) and are associated with increased tumor progression and metastasis. Therefore, high levels of prostaglandins may promote the development of malignancy. Although arsenite induces the expression of COX-2, the precise mechanism underlying these effects remains to be elucidated.
Here, we focus on determining whether Tpl2 is obligatory for arsenite-induced signal transduction. We provide evidence that Tpl2 is a mediator of arsenite-induced COX-2 expression and PGE 2 production in mouse epidermal JB6 P+ cells. Furthermore, extracellular signal-regulated kinases (ERK) and c-Jun NH 2 -terminal kinases (JNK) are the downstream effectors of Tpl2 for the mediation of NF-nB and activator protein-1 (AP-1) transactivation.
Materials and Methods
Materials. Eagle's MEM, gentamicin, and L-glutamine were obtained from Life Technologies. The Tpl2 kinase inhibitor [TKI; 4-(3-chlor-4-fluorophenylamino)-6-(pyridin-3-yl-methylamino)-3-cyano-1,7-naphthylridine] was purchased from Calbiochem-Novabiochem. The antibody against COX-2 was purchased from Cayman and the antibody against h-actin was from Sigma-Aldrich. The antibody against phosphorylated Tpl2 was obtained from Invitrogen and antibodies against total Tpl2 were obtained from Santa Cruz Biotechnology. Antibodies to detect phosphorylated ERK, total ERK, phosphorylated JNK, total JNK, phosphorylation MEK1, total MEK1, phosphorylated MKK4, and total MKK4 were from Cell Signaling Biotechnology. CNBr-Sepharose 4B, glutathione-Sepharose 4B, [g-32 P]ATP, and the chemiluminescence detection kit were purchased from Amersham Pharmacia Biotech, and the protein assay kit was obtained from Bio-Rad Laboratories.
Cell culture and short hairpin RNA transfection. The JB6 P+ mouse epidermal cell line was purchased from the American Type Culture Collection. JB6 P+ cells were cultured in monolayers in 5% fetal bovine serum (FBS)-MEM, 2 mmol/L L-glutamine, and 25 Ag/mL gentamicin at 37jC in a 5% CO 2 incubator. The JB6 P+ mouse epidermal cell line stably transfected with COX-2 luciferase reporter plasmid was a kind gift from Dr. Chauanshu Huang (School of Medicine, New York University). The JB6 mouse epidermal cell lines were stably transfected with an AP-1, NF-nB, or COX-2 luciferase reporter plasmid and maintained in MEM supplemented with 5% FBS containing 200 g/mL G418. Short hairpin RNA (shRNA) constructs against Mus musculus Tpl2 were purchased from Origene. For knockdown experiments, the cells were transfected with shRNA targeting M. musculus Tpl2 or with nontargeting control shRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Western blot assay. For the Western blot assay, cells (1.5 Â 10 6 ) were cultured in a 10-cm dish for 48 h and then starved in 0.1% FBS-MEM for 24 h to eliminate the FBS activation of MAPKs. Following treatment, cells were disrupted with lysis buffer [10 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 5 mmol/L EDTA, 1% Triton X-100, 1 mmol/L DTT, 0.1 mmol/L phenylmethylsulfonyl fluoride, 10% glycerol, and a protease inhibitor cocktail tablet]. The supernatant fractions were boiled for 5 min. The protein concentration was determined using a dye-binding protein assay kit (Bio-Rad Laboratories) as described by the manufacturer. Lysate proteins (30 Ag) were subjected to 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Amersham Pharmacia Biotech). After blotting, the membrane was incubated at 4jC overnight with the specific primary antibody. Protein bands were visualized using a chemiluminescence detection kit (Amersham Pharmacia Biotech) after hybridization with the horseradish peroxidase-conjugated secondary antibody.
Tpl2 immunoprecipitation and kinase assay. ]ATP solution were added, and the mixture was incubated for 10 min at 30jC. A 20 AL aliquot was transferred onto p81 paper and washed three times with 0.75% phosphoric acid for 5 min per wash followed by a single wash with acetone for 2 min. The radioactive incorporation was determined using a scintillation counter. Experiments were done in triplicate.
PGE 2 assay. Cells were plated in 24-well dishes, grown to 80% confluence in 500 AL growth medium for 48 h, and starved in 0.1% FBS-MEM for 24 h. Following treatment, culture medium was collected, centrifuged at 14,000 rpm for 5 min to remove cell debris, and frozen at À80jC before analysis. The amounts of PGE 2 released into the medium were measured using the PGE 2 enzyme immunoassay kit (Cayman Chemical). Experiments were done in triplicate.
Luciferase assay for COX-2, NF-KB, or AP-1 transactivation. Confluent monolayers of JB6 P+ cells stably transfected with a COX-2, NF-nB, or AP-1 luciferase plasmid were trypsinized, and 8 Â 10 3 viable cells suspended in 100 AL of 5% FBS-MEM were added to each well of a 96-well plate. Plates were incubated at 37jC in a humidified atmosphere of 5% CO 2 . When cells reached 80% to 90% confluence, they were starved by culturing in 0.1% FBS-MEM for another 24 h. The cells were treated with TKI for 30 min before they were exposed to 20 Amol/L arsenite for 24 h. After treatment, cells were disrupted with 100 AL lysis buffer [0.1 mol/L potassium phosphate (pH 7.8), 1% Triton X-100, 1 mmol/L DTT, and 2 mmol/L EDTA], and the luciferase activity was measured using a luminometer (Luinoskan Ascent, Labsystems).
Statistical analysis. Data are expressed as mean F SD. Student's t test was used for single statistical comparisons, with a probability of P < 0.05 as the criterion for statistical significance. proteins were determined by Western blot. C, arsenite induces Tpl2 kinase activity in a time-dependent manner. Cells were treated with 20 Amol/L arsenite and harvested at the indicated times. Cells were disrupted and kinase activity of Tpl2 was determined as described in Materials and Methods. Mean F SD of triplicate assays. **, P < 0.01, significant difference from untreated control. D, arsenite induces phosphorylation of Tpl2 in a dose-dependent manner. Cells were harvested 2 h after treatment with the indicated dose of arsenite. The level of phosphorylated Tpl2 or total Tpl2 protein was determined by Western blot. The relative value of density for p-Tpl2 bands was normalized to Tpl2.
Results
Arsenite strongly increases phosphorylation and kinase activity of Tpl2. To determine whether Tpl2 is involved in the cellular response to arsenite exposure (Fig. 1A) , we examined the phosphorylation of Tpl2 induced by arsenite in mouse epidermal JB6 P+ cells. Arsenite exposure caused a substantial elevation of Tpl2 phosphorylation (Fig. 1B) and kinase activity (Fig. 1C) in a time-dependent manner and also induced phosphorylation of Tpl2 in a dose-dependent manner (Fig. 1D) . These results indicate that arsenite induces phosphorylation and kinase activity of Tpl2 in JB6 P+ cells.
Arsenite induces COX-2 expression and PGE 2 secretion. We examined whether arsenite could induce COX-2 expression. A timeresponse study indicated that arsenite exposure led to an increase in COX-2 protein level from 6 to 24 h (Fig. 2A) . Arsenite also increased PGE 2 release in a time-dependent manner (Fig. 2B ) and increased COX-2 expression in a dose-dependent manner (Fig. 2C) . To further confirm this finding, we measured COX-2 transcription using a gene reporter assay. The promoter activity of COX-2 was significantly increased by arsenite exposure dose-dependently (Fig. 2D) . These results indicate that COX-2 expression, COX-2 promoter activity, and PGE 2 production are induced by exposure to arsenite time-and dose-dependently.
TKI suppresses arsenite-induced COX-2 expression. The above data indicated that arsenite induces Tpl2 kinase activity and also increases COX-2 expression and PGE 2 secretion. Therefore, we hypothesized that Tpl2 might play a key role in arsenite-induced COX-2 expression and PGE 2 production and that COX-2 expression would be changed by the inhibition of Tpl2 activation. As expected, we found that TKI, a Tpl2 inhibitor, markedly suppressed arsenite-induced COX-2 expression in a dosedependent manner (Fig. 3A) . TKI also inhibited arsenite-induced COX-2 promoter activity (Fig. 3B ) and substantially attenuated arsenite-induced PGE 2 production (Fig. 3C) . These results suggest that Tpl2 plays a critical role in arsenite-induced COX-2 induction and PGE 2 production.
Involvement of Tpl2 in COX-2 induction by arsenite. We used shRNA to confirm whether the Tpl2-dependent pathway is involved in the expression of COX-2 in the arsenite response. The expression of Tpl2 shRNA specifically reduced the Tpl2 protein level (Fig. 4A,  bottom) , and arsenite-induced COX-2 expression was inhibited in the Tpl2 shRNA cells compared with the control shRNA cells (Fig. 4A, top) . Tpl2 shRNA cells impaired arsenite-induced COX-2 promoter-driven luciferase activity in JB6 P+ cells stably transfected with a COX-2 luciferase plasmid (Fig. 4B) . Tpl2 shRNA cells also significantly inhibited arsenite-induced PGE 2 production (Fig. 4C) . Collectively, these results indicate that arsenite induces COX-2 expression and PGE 2 production through a Tpl2-dependent pathway.
Tpl2 regulates ERK and JNK activity. Previous studies have indicated that the MAPK signaling pathway is involved in arseniteinduced carcinogenesis in JB6 P+ cells (19, 20) . We found that Tpl2 is involved in arsenite-induced COX-2 expression; however, the signal transduction components mediated by arsenite-induced Tpl2 activation in JB6 P+ cells are unknown. We hypothesized that Tpl2 might be located upstream of the known arsenite-stimulated signal transduction pathway and that Tpl2 could regulate several downstream kinases. To determine the physiologic role of Tpl2 in MAPK activation induced by arsenite in JB6 P+ cells, we investigated the influence of TKI on arsenite-induced activation Figure 2 . Effect of arsenite on COX-2 expression and promoter activity and PGE 2 production. A, arsenite elevates COX-2 expression in a time-dependent manner. Cells were exposed to 20 Amol/L arsenite and harvested at the indicated time. Levels of COX-2 and h-actin proteins were determined by Western blot. B, arsenite stimulates PGE 2 secretion in a time-dependent manner. Cells were treated with 20 Amol/L arsenite for the indicated time. PGE 2 generation was determined using the PGE 2 assay kit as described in Materials and Methods. Mean F SD of triplicate experiments. **, P < 0.01, significant difference from untreated control. C, arsenite induces increased COX-2 expression in a dose-dependent manner. Cells were harvested 12 h after treatment with the indicated dose of arsenite. Levels of COX-2 and h-actin proteins were determined by Western blot. D, arsenite induces COX-2 promoter activity. JB6 P+ cells stably transfected with the COX-2 luciferase reporter plasmid were harvested 24 h after treatment with the indicated dose of arsenite. The relative activity was measured by luciferase assay as described in Materials and Methods. Mean F SD of COX-2 luciferase activities calculated from triplicate determinations. **, P < 0.01, significant difference from untreated control. The relative value of density for COX-2 bands was normalized to h-actin.
of the MEK/ERK and MKK4/JNK pathways. Our data showed that TKI substantially inhibited the phosphorylation of MEK and ERK (Fig. 5A, left) . In addition, TKI blocked phosphorylation of MKK4 and JNK (Fig. 5A, right) . To confirm these results, we examined arsenite-stimulated phosphorylation of ERK and JNK in control and Tpl2 shRNA-expressing cells. Arsenite-induced phosphorylation of ERK and JNK was attenuated in the Tpl2 shRNA cells compared with the control shRNA cells (Fig. 5B) . We also found that ERK and JNK were required for COX-2 induction by arsenite when JB6 P+ cells were treated with kinase inhibitors 30 min before Figure 4 . Role of Tpl2 in arsenite-induced COX-2 expression and PGE 2 production. A, Tpl2 shRNA reduces arsenite-induced COX-2 expression. JB6 P+ cells were transiently transfected with Tpl2 shRNA or control shRNA. 72 h after transfection, cells were treated with arsenite (10 or 20 Amol/L) for 12 h. The level of COX-2, h-actin, and Tpl2 proteins was determined by Western blot. B, Tpl2 shRNA inhibits arsenite-induced COX-2 promoter activity. JB6 P+ cells that were stably transfected with the COX-2 luciferase reporter plasmid were transiently transfected with Tpl2 shRNA or control shRNA and, 72 h after transfection, were treated with arsenite (0, 10, or 20 Amol/L) for 24 h. The relative activity was measured by luciferase assay as described in Materials and Methods. Mean F SD of COX-2 luciferase activities calculated from triplicate determinations. **, P < 0.01, significant difference between groups. C, Tpl2 shRNA reduces arsenite-induced PGE 2 secretion. JB6 P+ cells were transfected with Tpl2 shRNA or control shRNA and, 72 h after transfection, were treated with arsenite (0, 10, or 20 Amol/L) for 24 h. PGE 2 generation was determined using the PGE 2 assay kit as described in Materials and Methods. Mean F SD of triplicate determinations. **, P < 0.01, significant difference between groups. The relative value of density for COX-2 bands was normalized to h-actin. Figure 3 . Effect of TKI on arsenite-induced COX-2 expression and promoter activity and PGE 2 production. A, arsenite-induced COX-2 expression is attenuated by TKI. Cells were treated with TKI (0, 5, 10, or 20 Amol/L) for 30 min before being stimulated with 20 Amol/L arsenite for 12 h. The level of COX-2 and h-actin proteins was determined by Western blot using specific antibodies as described in Materials and Methods. B, arsenite-induced COX-2 promoter activity is attenuated by TKI. JB6 P+ cells stably transfected with the COX-2 luciferase reporter plasmid were pretreated with TKI (0, 5, 10, or 20 Amol/L) for 30 min before being exposed to 20 Amol/L arsenite for 24 h. The relative activity was measured by luciferase assay as described in Materials and Methods. Mean F SD of COX-2 luciferase activities calculated from triplicate determinations. *, P < 0.05; **, P < 0.01, significant difference between groups treated with arsenite and TKI combined and the group exposed to arsenite alone. C, arsenite-induced PGE 2 secretion is impaired by TKI. Cells were pretreated with TKI (0, 5, 10, or 20 Amol/L) for 30 min before being exposed to 20 Amol/L arsenite for 24 h. PGE 2 generation was determined using the PGE 2 assay kit as described in Materials and Methods. Mean F SD of triplicate determinations from one experiment. **, P < 0.01, significant difference between groups treated with arsenite and TKI combined and the group exposed to arsenite alone. The relative value of density for COX-2 bands was normalized to h-actin.
treatment with arsenite for 12 h. Finally, we observed that U0126 and SP600125, pharmacologic inhibitors of MEK and JNK, respectively, blocked arsenite-induced COX-2 expression (Fig. 5C) . However, SB203580, a p38 inhibitor, had no effect on arseniteinduced COX-2 expression (data not shown). These findings indicate that Tpl2 is an upstream kinase of MEK/ERK and MKK4/JNK and that it is also involved in arsenite-induced COX-2 expression.
Tpl2 regulates NF-KB and AP-1 activity. The COX-2 gene promoter region contains NF-nB and AP-1 binding sites that can be recognized by these transcription factors and, in turn, lead to cox-2 gene expression (21) . We examined whether NF-nB or AP-1 was a Tpl2 downstream transcription factor induced by arsenite. To determine whether the repression of COX-2 expression by TKI involved the inhibition of NF-nB or AP-1 activation, we measured NF-nB and AP-1 transactivation using JB6 cells stably transfected with an AP-1 or NF-nB luciferase reporter plasmid. Pretreatment of cells with TKI markedly inhibited arsenite-induced NF-nB and AP-1 activation (Fig. 6A and B) . A Tpl2 shRNA construct was transfected into JB6 P+ cells, which were then stably transfected with a NF-nB or AP-1 luciferase plasmid. Arsenite treatment decreased NF-nBand AP-1-dependent transcriptional activity in Tpl2 shRNA cells compared with control shRNA cells (Fig. 6C and D) . These data show that NF-nB and AP-1 are downstream regulators of Tpl2 for arsenite-induced COX-2 expression.
Discussion
Arsenite is a well-known skin carcinogen that has the ability to activate signaling pathways and gene expression. Here, we provide the first direct evidence that arsenite leads to the activation of Tpl2, which plays a critical role in arsenite-induced PGE 2 production through the induction of COX-2 expression. Moreover, Tpl2 appears to function upstream of MEK/ERK and MKK4/JNK, which leads to induction of cox-2 expression through its downstream NF-nB and AP-1 signaling pathways. Our data indicate that the activation of Tpl2 is a major event involved in arsenite-induced carcinogenesis.
The Tpl2 proto-oncogene encodes a serine/threonine protein kinase that is activated by provirus insertion in T-cell lymphoma induced by Moloney leukemia virus and mouse mammary tumor virus-induced mammary carcinomas (6, 7) . Investigations of Tpl2 expression in human tumor specimens have shown that Tpl2 is overexpressed in various cancer cells (13, 14) . We recently reported a link between the phosphorylation of Tpl2 and neoplastic cell transformation (22) . Previous studies have shown that arsenite induces COX-2 expression, which is mediated through the IKKh/ NF-nB pathway in JB6 P+ cells (23) . However, little is known about the upstream mediators of arsenite-induced COX-2 expression and PGE 2 synthesis. Here, we found that arsenite strongly induces phosphorylation and kinase activity of Tpl2 (Fig. 1) . Accumulating evidence suggests that oxidative stress occurs in response to arsenic exposure and may be a factor in dermal arsenic carcinogenesis (24) . Additionally, reactive oxygen species can act as signaling molecules by activating various cellular processes (25) . Thus, the generation of reactive oxygen species by arsenite may be associated with various cellular processes, such as Tpl2 activation.
COX-2, a key enzyme in PGE 2 synthesis, is maintained at low levels in normal cells but is induced by inflammatory tumor promoters, cytokines, growth factors, and oncogenes (26) . COX-2 knockout mice developed f75% fewer chemically induced skin papillomas than control mice (27) . The present study provides evidence that arsenite can induce COX-2 expression and PGE 2 production in JB6 P+ cells. Arsenite induced COX-2 expression, COX-2 promoter activity, and PGE 2 production in a time-and dosedependent manner. Inhibition of Tpl2 dramatically impaired arsenite-induced expression of COX-2. Moreover, knockdown of Tpl2 expression by shRNA abrogated arsenite-induced COX-2 expression and PGE 2 generation. These results strongly suggest that Tpl2 is involved in arsenite-stimulated COX-2 expression and PGE 2 secretion.
Tpl2 is a pivotal member of several intracellular signaling pathways. Previous studies showed that overexpression of Tpl2 leads to activation of MAPKs (12, 28) . Our results show that TKI significantly suppresses the phosphorylation of the MEK/ERK and MKK4/JNK signaling pathways, and Tpl2 shRNA reduces arseniteinduced ERK and JNK phosphorylation. The results indicate that ERK and JNK activation depends on Tpl2. Moreover, U0126 and SP600125, which are MEK and JNK inhibitors, respectively, strongly suppressed arsenite-induced COX-2 expression. Overall, these data suggest that Tpl2 functions upstream of MEK/ERK and MKK4/JNK and that it is involved in arsenite-induced COX-2 expression.
MAPKs are upstream activators of transcription factors such as NF-nB and AP-1, which are implicated in COX-2 expression (29, 30) . The cox-2 gene contains binding sites for several important transcription factors, including NF-nB and AP-1. Increases in NF-nB-DNA or AP-1-DNA binding immediately precede upregulation of cox-2 gene transcription in various cell lines. NF-nB was reported as an upstream mediator of COX-2 expression in mouse epidermal JB6 P+ cells (23) . A correlation between AP-1 and COX-2 expression has been suggested. AP-1 has been shown to promote tumor-induced expression of COX-2 in mouse skin (31) . We found that arsenite could induce transactivation of AP-1 in JB6 P+ cells (32) . These previous studies provided strong evidence showing that NF-nB and AP-1 are involved in arsenite-induced COX-2 expression in JB6 P+ cells.
In the present study, we further examined the arsenite-induced Tpl2 activity leading to NF-nB and AP-1 transactivation. Pretreatment with TKI significantly reduced arsenite-induced transactivation of NF-nB and AP-1. In Tpl2 shRNA cells, arsenite treatment did not lead to obvious enhancement of NF-nB or AP-1 transactivation compared with control shRNA cells. Thus, these data indicate that Figure 6 . Involvement of Tpl2 in arsenite-induced NF-nB and AP-1 activation. A and B, TKI reduces arsenite-induced NF-nB (A ) and AP-1 (B ) transcriptional activities in JB6 P+ cells. JB6 P+ cells that were stably transfected with a NF-nB or AP-1 luciferase reporter plasmid were treated with TKI (5, 10, or 20 Amol/L) for 30 min before being exposed to 20 Amol/L arsenite for 24 h. The relative activity was measured by luciferase assay as described in Materials and Methods. Mean F SD of NF-nB or AP-1 luciferase activities calculated from triplicate determinations. **, P < 0.01, significant difference between groups treated with arsenite and TKI combined and the group exposed to arsenite alone. C and D, Tpl2 shRNA inhibits arsenite-induced NF-nB (C ) and AP-1 (D ) promoter activity. JB6 P+ cells that were stably transfected with the NF-nB or AP-1 luciferase reporter plasmid were transiently transfected with Tpl2 shRNA or control shRNA. 72 h after transfection, cells were treated with arsenite (0, 10, or 20 Amol/L) for 24 h. The relative activity was measured by luciferase assay as described in Materials and Methods. Mean F SD of NF-nB or AP-1 luciferase activities calculated from triplicate determinations. **, P < 0.01, significant difference between groups.
Tpl2 is involved in NF-nB and AP-1 arsenite-induced transactivation.
Based on these results, we propose a model for arsenite-induced Tpl2 activation and the associated signaling pathways. According to this model, arsenite induces COX-2 expression and PGE 2 synthesis, which is mediated by the activation of Tpl2. In addition, arsenite triggers a Tpl2-dependent MEK/ERK and MKK4/JNK pathway that leads to the activation of NF-nB and AP-1. These findings provide new insight into the molecular mechanisms of the tumor promotion effects of arsenite and suggest that Tpl2 is an excellent target for the development of drugs to fight arseniteinduced skin carcinogenesis.
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